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Abstract
Background: The effects of gonadotrophin-releasing hormone agonist (GnRH-a) administered in the luteal phase
remains controversial. This meta-analysis aimed to evaluate the effect of the administration of a single-dose of
GnRH-a in the luteal phase on ICSI clinical outcomes.
Methods: The research strategy included the online search of databases. Only randomized studies were included.
The outcomes analyzed were implantation rate, clinical pregnancy rate (CPR) per transfer and ongoing pregnancy
rate. The fixed effects model was used for odds ratio. In all trials, a single dose of GnRH-a was administered at day
5/6 after ICSI procedures.
Results: All cycles presented statistically significantly higher rates of implantation (P < 0.0001), CPR per transfer (P =
0.006) and ongoing pregnancy (P = 0.02) in the group that received luteal-phase GnRH-a administration than in
the control group (without luteal-phase-GnRH-a administration). When meta-analysis was carried out only in trials
that had used long GnRH-a ovarian stimulation protocol, CPR per transfer (P = 0.06) and ongoing pregnancy (P =
0.23) rates were not significantly different between the groups, but implantation rate was significant higher (P =
0.02) in the group that received luteal-phase-GnRH-a administration. On the other hand, the results from trials that
had used GnRH antagonist multi-dose ovarian stimulation protocol showed statistically significantly higher
implantation (P = 0.0002), CPR per transfer (P = 0.04) and ongoing pregnancy rate (P = 0.04) in the luteal-phase-
GnRH-a administration group. The majority of the results presented heterogeneity.
Conclusions: These findings demonstrate that the luteal-phase single-dose GnRH-a administration can increase
implantation rate in all cycles and CPR per transfer and ongoing pregnancy rate in cycles with GnRH antagonist
ovarian stimulation protocol. Nevertheless, by considering the heterogeneity between the trials, it seems premature
to recommend the use of GnRH-a in the luteal phase. Additional randomized controlled trials are necessary before
evidence-based recommendations can be provided.
Background
The depletion of granular cells due to follicular aspiration
and the suppression of the release of luteinizing hormone
(LH) by analogues (agonists and antagonists) of gonado-
trophin-releasing hormone (GnRH) have been associated
with a defect of the luteal phase in cycles of assisted
reproduction. Furthermore, controlled ovarian stimula-
tion was shown to be capable of accelerating endometrial
maturation, hindering receptivity to embryo implantation
[1]. Thus, through the years, there has been a continuous
concern about the occurrence of luteal phase deficiency,
principally in IVF/ICSI cycles [2,3], making the utilization
of hCG, progesterone and sometimes estradiol (E2) a
routine procedure in assisted reproduction technology
(ART) to support the luteal phase. Recently, attention
has been given to therapy with gonadotrophin-releasing
hormone agonist (GnRH-a).
The effects of GnRH-a administration in the luteal phase
has been the focus of different studies. Lemay et al. [4,5]
suggested that GnRH-a can act as a luteolytic agent due to
desensitization of GnRH receptors. Furthermore, Dubour-
dieu et al. [6] and Herman et al. [7] reported deterioration
of corpus luteum function with the administration of
GnRH-a. However, attempts to interrupt pregnancy or
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any medium, provided the original work is properly cited.even prevent implantation have not been impressive [8,9].
On the other hand, a series of studies show that the inad-
vertent administration of GnRH-a in the luteal phase does
not compromise the continuity of pregnancy, and sug-
gested, to the contrary, a possible favorable effect on
implantation [10-14]. Recently, different studies analyzing
single [15-18] or multiple administrations [19-22] of medi-
cation have, in fact, suggested a beneficial effect in sup-
porting the luteal phase. The mechanism of the presumed
beneficial effect is poorly defined. It was suggested that
GnRH-a can collaborate in the maintenance of the corpus
luteum, acting directly on the endometrium via local
receptors, a direct effect on the embryos or by some com-
bination of these possibilities. On the other hand, other
authors did not confirm positive action from the adminis-
tration of GnRH-a in the luteal phase [23-25].
This meta-analysis aimed to evaluate the effect of the
administration of single-dose GnRH-a in the luteal
phase on IVF/ICSI clinical outcomes in ovarian stimula-
tion protocols using GnRH antagonist (GnRH-ant)
multi low-dose ovarian stimulation protocol or long
GnRH-a ovarian stimulation protocol.
Methods
Criteria for considering studies for this meta-analysis
All published and ongoing randomized controlled trials
assessing the effect of single dose GnRH-a administra-
tion in luteal support on IVF/ICSI outcomes were
included. Frozen embryo replacement and egg donation
cycles were not included. Due to the large difference in
GnRH-a application schemes, studies with multiple
applications of GnRH-a in the luteal phase were
excluded.
Outcome measures
The outcome measures used for this meta-analysis were
implantation rate, clinical pregnancy rate (CPR) per
transfer and ongoing pregnancy rate.
Identification of studies
Search strategies included online surveys of databases
(MEDLINE, EMBASE, Science Citation Index, Cochrane
Controlled Trials Register and Ovid) from 1980 to 2010.
There was no language restriction. The following medi-
cal subject headings and text words were used: GnRH
agonist, luteal phase, luteal phase support, luteal phase
administration, IVF, ICSI and randomized controlled
trial. The principal inclusion criterion was randomized
controlled trial (RCT).
Search results
Among the 12 potentially relevant studies retrieved, a
total of 5 trials fulfilled the inclusion criteria
[15,16,18,23,24]. A flow diagram of the selection process
is shown in Fig 1.
Description of the studies, validity assessment and data
extraction
Each trial was assessed independently by three reviewers
(JBAO, RB and JGF) and ranked for its methodological
rigor and its potential to introduce bias. Missing data
were obtained from the authors when possible.
In two trials [16,24] the long GnRH-a (leuprolide: 1,
buserelin: 1) ovarian stimulation protocol starting in the
mid-luteal phase of the preceding cycle was used as a
reference treatment, in two [15,23] the GnRH-ant
(cetrorelix: 1, cetrorelix/ganirelix: 1) multi low-dose
ovarian stimulation protocol was applied and in one
[18] both ovarian stimulation protocol types were used.
In all studies ICSI was performed. Table 1 summarizes
the main characteristics of the included trails.
Description of the studies
Tesarik et al., 2006 [18] - This prospective randomized
study evaluates the effect of GnRH-a administered in
the luteal phase on ICSI outcomes in both GnRH-a-
and GnRH-ant-treated ovarian stimulation protocols.
Six hundred women (300 using a long GnRH-a protocol
and 300 using a GnRH-ant protocol) were enrolled.
Patients treated with each of these two protocols were
randomly assigned to receive a single injection of
GnRH-a (0.1 mg of triptorelin) or placebo 6 days after
ICSI. Irrespective of whether GnRH-a was used as
luteal-phase support or not, all women were given 4 mg
of E2 valerate daily, 400 mg of vaginal micronized pro-
gesterone daily from the day of oocyte recovery for 17
days and an injection of 250 μg of HCG on the day of
embryo transfer. In the results it was observed in
GnRH-a-treated ovarian stimulation cycles a significant
improvement of implantation and live birth in luteal-
phase GnRH-a group as compared with placebo. In
GnRH-ant-treated ovarian stimulation cycles, luteal-
phase GnRH-a also increased ongoing pregnancy rate.
Ata et al., 2008 [24] - This double blind, randomized,
placebo controlled trial evaluates whether a single dose
GnRH-a administered 6 days after ICSI increases
ongoing pregnancy rates in cycles stimulated with the
long GnRH-a protocol. Five hundred and seventy
women were included. In addition to routine luteal
phase support with vaginal progesterone gel (90 mg),
women were randomized to receive a single 0.1 mg dose
of triptorelin or placebo 6 days after ICSI. Randomiza-
tion was done on the day of ET according to a compu-
ter generated randomization table. There were 89
(31.2%) ongoing pregnancies in the GnRH agonist
group, and 84 (29.5%) in the control group.
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rates were likewise similar in the GnRH agonist and pla-
cebo groups.
Isik et al., 2009 [15] - The study population consisted
of 164 patients who underwent ICSI after ovulation
induction by gonadotrophins and GnRH-ant for the pre-
vention of a premature LH surge. For luteal-phase sup-
port, all the cases received intravaginal 600 mg
micronized progesterone. In this prospective study,
patients were randomly assigned to two groups. In one
group, patients received an additional single dose of
GnRH-a (0.5 mg leuprolide acetate) subcutaneously on
day 6 after ICSI, whereas the patients in the other group
did not. Although the number of embryos transferred
and the grade of the embryos were similar in the two
groups, the patients in the luteal-phase agonist group
had significantly higher rates of implantation and clini-
cal pregnancy rates (P < 0.05).
Razieh et al., 2009 [16] - The aim of this study was to
assess the effect of single dose GnRH-a administered 3
days after embryo transfer, as luteal phase support, on
ICSI cycles stimulated with the long GnRH-a protocol.
One hundred and eighty women were enrolled. Patients
w e r er a n d o m l ya s s i g n e dt or e c e i v eas i n g l ed o s eo f
GnRH-a (0.1 mg of triptorelin) or placebo. The luteal
phase was supported by administration of progesterone
800 mg daily in all the cases. It was observed that the
patients in the luteal-phase GnRH-a group had a signifi-
cant improvement in implantation rate (12.3% vs. 7.3%)
and clinical pregnancy rate (25.5% vs. 10.0%) as com-
pared with placebo.
Ata and Urman, 2010 [23] - This trial evaluated
whether a single dose GnRH-a administered 6 days after
ICSI increases ongoing pregnancy rates in cycles stimu-
lated with the long GnRH-ant protocol. Ninety women
were included. In addition to routine luteal phase
Figure 1 QUOROM statement flow diagram illustrating selection of trials included in the meta-analysis. RCT: randomized controlled trial.
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were randomized to receive a single 0.1 mg dose of trip-
torelin or placebo 6 days after ICSI. In the results it was
observed a significant reduction in implantation and
ongoing pregnancy rates in luteal GnRH-a group as
compared with placebo. Clinical pregnancy rates were
similar in the GnRH-a and placebo groups.
Statistical analysis
Data management and analysis were conducted using
the StatsDirect statistical software (Cheshire, UK). The
fixed effect model was used for odds ratio (OR) and the
effectiveness was evaluated by the Mantel-Haenszel
method. A confidence interval (CI) was calculated using
the variance formula of Robins, Breslow and Greenland.
A chi-squared test statistic was used with its associated
probability that the pooled OR was equal to 1. The mea-
sure of heterogeneity (non-combinability) was evaluated
by Cochran’sQ ,t h eB r e s l o w - D a ya n dI
2 tests. A non-
significant result (i.e. lack of heterogeneity) indicates
that no trial had an OR significantly worse or better
than the overall common OR obtained by pooling the
data. Since a fixed effects model has been employed
herein, it is important to acknowledge that inferences
refer only to the particular studies included in the analy-
sis. Meta-analysis used in this manner is simply a device
to pool the information from the various studies to pro-
vide a composite finding, but only for those studies.
Since many of the preceding analyses contained only
two or three studies, it was decided to derive the infer-
ences from a fixed-effects model.
Results
Implantation rate (Fig 2)
Four studies were included [15,18,23,24]. The pooled
implantation rate was significantly higher in the group
of patients that received GnRH-a in the luteal phase
(24.4%, 411/1686) than in the group that did not receive
this hormone agonist (18.6%, 335/1798) (P < 0.0001; OR
= 1.40, 95% CI 1.19, 1.65). There was heterogeneity in
this comparison (Breslow-Day = 31.52, df = 3, P <
0.0001; Cochran Q = 30.40, df = 3, P < 0.0001; I
2 =
90.1%, 95% CI = 75.6% to 94.5%).
In the subgroup of trials where the long GnRH-a
ovarian stimulation protocol was used [18,24], the
pooled implantation rate was significantly greater in the
group of patients that received GnRH-a in the luteal
phase (24%, 259/1080) than in the group that did not
Table 1 Main characteristics of randomized controlled trials (RCT) on the use of GnRH in luteal phase
Trial Randomization Protocol stimulation Luteal Phase Results
Study group
GnRH-a
Control
group
Others medicines
(all patients)
Tesarik et al.,
2006 [18]
Embryo transfer
day
Computer
generated list
Opaque envelopes
Blinding
GnRH-a long protocol/
GnRH-ant multiple dose
+
r-FSH/HMG
+
r-HCG
n:150 GnRH-a
long protocol)
n:150 GnRH-ant
protocol
Single injection
Dose:0.1 mg/
triptorelin
Day 6 after ICSI
n:150
(GnRHa-
long
protocol)
n:150
(Antagonist
protocol)
Placebo
E2 valerate (4 mg)
+
Vaginal micronized
progesterone(400 mg)
+
r-HCG (single dose)
Improvement implantation/
live birth rates
Ata et al.,
2008 [24]
Embryo transfer
day
Computer
generated list
Opaque envelopes
Blinding
GnRH-a long protocol
+
r-FSH
+
HCG
n:285
Single injection
Dose:0.1 mg/
triptorelin
Day 6 after ICSI
n:285
Placebo
Vaginal progesterone
gel/90 mg
No differences
Isik et al.,
2009 [15]
Embryo transfer
day
Computer
generated list
Blinding
GnRH-ant multiple dose
+
r-FSH/HMG
+
hCG/r-hCG
n:74
Single injection
Dose:0.5 mg/
leuprolide
Day 6 after ICSI
n:80
No placebo
Vaginal micronized
progesterone(600 mg)
+
HCG(single dose)
Improvement implantation/
clinical pregnancy rates
Razieh et al.,
2009 [16]
Drawing piece of
paper from a bag
GnRH-a long protocol
+
r-FSH
+
HCG
n:90
Single injection
Dose:0.1 mg/
triptorelin
Day 5/6 after
ICSI
n:90
Placebo
Vaginal micronized
progesterone(800 mg)
Improvement implantation/
clinical pregnancy rates
Ata and
Urman, 2010
[23]
Embryo transfer
day
Computer
generated list
Opaque envelopes
Blinding
GnRH-ant multiple dose
+
r-FSH/HMG
+
r-HCG
n:38
Single injection
Dose:0.1 mg/
triptorelin
Day 6 after ICSI
n:52
Placebo
Vaginal progesterone
gel/90 mg
Lower Implantation/
ongoing pregnancy rates
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Page 4 of 11Figure 2 Fixed-effect model. Forest plot for implantation rates. A: All cycles; B: Only cycles with long GnRH agonist ovarian stimulation
protocol; C: Only cycles with GnRH antagonist multi low-dose ovarian stimulation.
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Page 5 of 11receive it (20%, 224/1122) (P = 0.02; OR = 1.26, 95% CI
1.03, 1.54). There was heterogeneity in this comparison
(Breslow-Day = 7.25, df = 1, P = 0.007; Cochran Q =
7.21, df = 1, P = 0.007). Similarly, in the subgroup of
trials where the GnRH-ant multi low-dose ovarian sti-
mulation protocol was used [15,18,23], the pooled
implantation rate was also significantly higher in the
group of patients that received GnRH-a in the luteal
phase (25.1%, 152/606) than in the group not adminis-
tered this substance (16.4%, 111/676) (P = 0.0002; OR =
1.70, 95% CI 1.29, 2.23). There was heterogeneity in this
comparison (Breslow-Day = 20.46, df = 2, P < 0.0001;
Cochran Q = 20.17, df = 2, P <0.0001; I
2 = 90.1%, 95%
CI = 66.9% to 95%)
Clinical pregnancy rate per transfer (Fig 3)
Five studies were included [15,16,18,23,24]. The pooled
CPR per transfer was significantly higher in the group of
patients administered GnRH-a in the luteal phase
(42.4%, 328/773) than in the group that did not receive
it (35.7%, 283/793) (P = 0.006; OR = 1.33, 95% CI 1.08,
1.64). There was heterogeneity in this comparison (Bre-
slow-Day = 15.65, df = 4, P = 0.003; Cochran Q = 15.32,
df = 4, P = 0.004; I
2 = 73.9%, 95% CI = 0% to 87.5%).
However, in the subgroup of trials where the long
GnRH-a ovarian stimulation protocol was used
[16,18,24], the pooled CPR per transfer did not differ
significantly between the group of patients that received
GnRH-a in the luteal phase (42%, 217/516) versus the
group that did not receive it (36.4%, 188/517) (P = 0.06;
OR = 1.28, 95% CI 0.99, 1.65), a comparison with het-
erogeneity (Breslow-Day = 6.42, df = 2, P = 0.04;
C o c h r a nQ=6 . 2 5 ,d f=2 ,P=0 . 0 4 ;I
2 =6 8 % ,9 5 %C I=
0% to 88.6%). On the other hand, in the subgroup of
trials where the GnRH-ant ovarian stimulation protocol
was used [15,18,23], the CPR per transfer was signifi-
cantly higher in the group of patients that received
GnRH-a in the luteal phase (43.2%, 111/257) than in the
group that were not administered this hormone agonist
(34.4%, 95/276) (P = 0.04; OR = 1.44, 95% CI 1.01,
2.05). There was heterogeneity in this comparison (Bre-
s l o w - D a y=8 . 9 4 ,d f=2 ,P=0 . 0 1 ;C o c h r a nQ=8 . 7 4 ,d f
= 2, P = 0.01; I
2 = 77.1%, 95% CI = 0% to 90.9%)
Ongoing pregnancy rate (Fig 4)
Four studies were included [15,18,23,24]. The pooled
ongoing pregnancy rate was significantly greater in the
group of patients that received GnRH-a in the luteal
phase (37%, 253/683) than in the group that did not
receive it (31.1%, 219/703) (P = 0.02; OR = 1.29, 95% CI
1.03, 1.62), a heterogeneous comparison (Breslow-Day =
14.94, df = 3, P = 0.001; Cochran Q = 14.23, df = 3, P =
0.002; I
2 = 78.9%, 95% CI = 7.9% to 90.2%).
However, in the subgroup of trials where the long
GnRH-a ovarian stimulation protocol was used [18,24],
the pooled ongoing pregnancy rate was not signifi-
cantly different between the patients that received
(36.4%, 155/426) versus the group that did not receive
GnRH-a in the luteal phase (32.3%, 138/427) (P = 0.23;
OR = 1.20, 95% CI 0.90, 1.59). There was no heteroge-
neity in this comparison (Breslow-Day = 0.84, df = 1,
P = 0.35; Cochran Q = 0.84, df = 3, P = 0.25). On the
other hand, in the subgroup of trials where the GnRH-
ant ovarian stimulation protocol was used [15,18,23],
the pooled ongoing pregnancy rate was significantly
elevated in the group of patients that received GnRH-a
in the luteal phase (38.1%, 98/257) in relation to the
group that did not receive it (29.3%, 81/276) (P = 0.04;
OR = 1.46, 95% CI 1.02, 2.10), a comparison with het-
erogeneity (Breslow-Day = 13.6, df = 2, P = 0.001;
C o c h r a nQ=1 2 . 7 ,d f=2 ,P=0 . 0 0 1 ;I
2 = 84.4%, 95%
CI = 16.9% to 93.1%).
Discussion
The increasing volume of information has stimulated a
growing need for reviews of the medical literature.
Meta-analysis differs from the narrative review by its
rigorous and complete quantitative and qualitative
methodological approaches. It is an analytical approach
where different and independent studies are integrated
and the results combined into a unique common result.
When it is compared with narrative review, meta-analy-
sis has the great advantage of being less influenced by
the personal opinion of the reviewer thus providing
impartial conclusions. Moreover, all of the results can
easily be recalculated and compared with the authors’
conclusions. The meta-analysis, even when not produ-
cing definite conclusions about the utility of a treatment,
can support the necessity for new randomized trials on
the subject. Different RCTs evaluating the effects of
luteal GnRH-a administration on clinical outcomes have
been published recently but with divergent conclusions
[15,16,18,23,24]. Therefore, given the clinical potential
of this practise, a review about this subject would seem
to be helpful.
It has been suggested that a meta-analysis should be
patient oriented, i.e. primary outcomes should be clinical
results, which predict a better outcome and/or a more
advantageous cost/effectiveness ratio. In this type of
meta-analysis, GnRH-a administration in the luteal
phase produced a favorable effect not only on the gen-
eral implantation rate but also on the implantation rate
for both subgroups. In addition, luteal GnRH-a treat-
ment produced a significantly higher clinical pregnancy
rate in the group administered the GnRH-ant multi-
dose ovarian stimulation protocol. On the basis of these
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Page 6 of 11Figure 3 Fixed-effect model. Forest plot for clinical pregnancy rates per transfer. A: All cycles; B: Only cycles with long GnRH agonist ovarian
stimulation protocol; C: Only cycles with GnRH antagonist multi low-dose ovarian stimulation.
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Page 7 of 11Figure 4 Fixed-effect model. Ongoing clinical pregnancy rates. A: All cycles; B: Only cycles with long GnRH agonist ovarian stimulation
protocol; C: Only cycles with GnRH antagonist multi low-dose ovarian stimulation.
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Page 8 of 11data, it may seem attractive to consider administration
of a single dose of GnRH-a in the IVF/ICSI luteal phase
to improve clinical outcomes, especially in GnRH
antagonist cycles. Other RCTs not included in this
meta-analysis [19,20] yielded the same results. Although
these trials were performed in different conditions
(GnRH agonist administration was continued until 14
days after oocyte retrieval; GnRH agonist administration
on the day of ovum pickup, on the day of embryo trans-
fer and three days thereafter, respectively), their out-
comes are clearly consistent with those of this meta-
analysis (i.e. increase in implantation rate) and support
the hypothesis that GnRH-a administration in luteal
phase may be useful.
Nevertheless, meta-analysis also presents problems.
Heterogeneity and insufficient power (low sample size)
hinder the ability to draw inferences about the meta-
analysis, which failed to show any statistically significant
difference in the clinical pregnancy rate and ongoing (in
GnRH-a long protocol cycles) pregnancy rate. This
observation can be related to a small cumulative sample
size. In the long GnRH-a ovarian stimulation protocol,
based on the CPR per transfer obtained in the groups
with and without luteal GnRH-a (42%, 217/516 and
36.4%, 188/517), the ability to detect a difference of 5%
with a power of 80% would require around 2450
patients to reach a definitiv ec o n c l u s i o n ,i . e .as a m p l e
size above the total number included. Similarly, still In
the long GnRH-a ovarian stimulation protocol, based on
the ongoing pregnancy rates obtained in the groups
with and without luteal GnRH-a (36.4%, 155/426 and
32.3%, 138/427), detecting a 5% difference with 80%
power would require around 4300 patients to draw a
definitive conclusion. Thus, for a more consistent con-
clusion, this meta-analysis guides researchers to wait for
the results of new RCTs that have more information
about clinical parameters.
One must be aware of the fact that a number of other
significant predictors of the outcomes exist in an indivi-
dual patient. Given that heterogeneity was observed in
most of the comparisons carried out in this meta-analy-
sis, a detailing of these studies should be made. Tesarik
et al. [18] asserts that the effect of luteal-phase GnRH
agonist administration should be interpreted in the con-
text of luteal-phase support. However, it can be seen
that the luteal phases were differently managed among
the trials: Tesarik et al. [18]: Vaginal micronized proges-
terone(400 mg) + r-HCG (single dose) +E2 valerate; Ata
et al [24] and Ata and Urman [23]: Vaginal progesterone
gel/90 mg; Isik et al. [15]: Vaginal micronized progester-
one(600 mg) + HCG(single dose); Razieh et al. [16]:
Vaginal micronized progesterone(800 mg). This differ-
ence among the populations may have contributed to
the divergent results obtained and, consequently, to the
heterogeneity observed in this meta-analysis. Again,
future controlled trials will clarify this issue.
The beneficial effects on clinical variables observed
herein, despite the differences in the luteal-phase back-
ground, and the fact the drug can be easily prescribed,
make the possibility of administering GnRH-a in ICSI
luteal phase support appear more attractive. However,
there is a need for discussion regarding the possible
mechanisms of GnRH-a luteal action. The hypothesis
that GnRH-a exerts a direct beneficial effect on the
embryos [17] is supported by different observations.
Animal experiments suggest that GnRH-a can improve
the in vitro development of the embryo [26-29]. In addi-
tion, GnRH appears to exert regulatory activity in the
synthesis and secretion of HCG by pre-implanted
embryos and by the placenta [30,31]. Tesarik et al. [18]
suggest possible direct effects on the embryo on account
of observation of higher levels of serum ß-HCG in the
overall group of patients who achieved a pregnancy after
luteal-phase administration of GnRH-a as compared
with placebo. On the other hand, given that the medica-
tion is administered in the presence of the embryos,
such improvement in clinical outcomes should be care-
fully weighed against possible harmful effects on the
health of resulting children. The relatively secure notion
that exposure of embryos to GnRH-a is not prejudicial
is based on a series of case reports on its accidental
administration to pregnant women that, in general,
report only on early postnatal examination of the chil-
dren [10-14]. Thus, further long-term follow-ups of
such children are still necessary to elucidate this point.
A direct action on uterine tissue may also be responsi-
ble for the effects of GnRH-a in the luteal phase. A pre-
sence of GnRH receptor with a dynamic pattern (more
intense in the luteal phase) was demonstrated in human
endometrium both in the epithelium and stroma
[32-34]. Moreover, it has been also reported that GnRH
and GnRH-a can alter the activity of matrix metallopro-
teinases, involved in tissue remodeling (matrix degrada-
tion) inherent to the process of endometrial trophoblast
invasion [35,36], and induce apoptosis in endometrial
cells in vitro [37,38]. However, in vitro GnRH analogues
do not seem to have significant influence on the extent
of decidualization of endometrial stromal cells in vitro
[32] nor do they have major direct effects on gene
expression of human endometrial epithelial cells [39].
Thus, despite the studies suggesting a direct action on
endometrial function, clinically relevant endometrial
effects of the GnRH analogues still need to be
established.
The corpus luteum is another possible GnRH-a target in
the luteal phase, though it is questioned whether such
action would occur through the secretion of pituitary hor-
mones or by direct action in the ovary. In cycles with
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luteum activity by GnRH-a may result from stimulation of
LH secretion, given that, despite the blockade, the pituitary
remains responsive to the administration of GnRH or
GnRH-a [15]. By contrary reasoning, in the long GnRH-a
ovarian stimulation protocol, such action would likely be
directly on the corpus luteus, since the pituitary blockade
may still be present at the moment of GnRH-a administra-
tion [24]. In any case, independent of the probable action
mechanism, Tesarik et al. [18] observed under both proto-
cols, long GnRH-a ovarian stimulation or GnRH-ant multi
low-dose ovarian stimulation, the increase in serum con-
centrations of E2 and progesterone in the luteal phase of
patients that received GnRH-a 6 days after ICSI relative to
those that were administered a placebo. Nevertheless,
Hugues et al. [40], in GnRH-ant cycles, observed no differ-
ences in the hormonal profile of the luteal phase after
GnRH-a administration.
In conclusion, the findings of this meta-analysis
demonstrate that the luteal-phase single-dose GnRH-a
administration can improve clinical outcomes after ICSI.
However, by considering the heterogeneity between the
trials, it seems premature to recommend the use of
GnRH-a in the luteal phase. Additional randomized con-
trolled trials are necessary before evidence-based recom-
mendations can be provided. Protocols, safety, side
effects and exact action mechanism(s) should de ana-
lyzed before the adoption of GnRH-a administration in
the luteal phase.
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